ANDA 203040, held by Eugia Pharma. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 203040 (Lidocaine Hydrochloride Preservative Free), held by Eugia Pharma, was first approved by FDA on Mar 14, 2013, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine hydrochloride injection is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 14, 2013 | Original application | Approved | None posted |
| Lidocaine Hydrochloride Preservative Free1% · injectable;injection | Lidocaine Hydrochloride | Discontinued |
| Lidocaine Hydrochloride Preservative Free2% · injectable;injection | Lidocaine Hydrochloride | Discontinued |
| Nov 5, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 14, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters